Topic 3: What Evidence Supports Earlier Intervention?
Real-world secukinumab data also support the hypothesis that lower therapeutic burden and shorter treatment delay may be associated with earlier or better response. Patients who had 5 or more treatment courses (including courses of antibiotics and procedures, like incision and drainage) prior to secukinumab were half as likely to respond to therapy. These observational findings are not randomized proof of disease modification, but they reinforce the clinical cost of allowing ineffective care to continue indefinitely.3
Recent expert frameworks describe moderate HS and progression using active tunnels, inflammatory lesion burden, inadequate control with conventional therapy, new regions, and new or extending tunnels. They also emphasize close reassessment for patients approaching moderate disease thresholds.4
| Evidence boundary: The window of opportunity is a treatment principle supported by observational evidence and expert frameworks. The exact duration of the window, the optimal intervention for every phenotype, and the degree to which early therapy prevents irreversible progression remain incompletely defined. |